Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems a... (/p Schedule of Events Sunday Octobe...)

HOME >> MEDICINE >> TECHNOLOGY

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

Date:10/10/2008

/p>

Schedule of Events

Sunday, October 12 (all times are ET)

-- TAXUS ATLAS Workhorse, Direct Stenting, Small Vessel and Long Lesion studies. Three-year data from the TAXUS ATLAS Workhorse study and two-year data from the TAXUS ATLAS Direct Stent study will be presented by the study's co-principal investigator Mark A. Turco, M.D., in an e-poster session titled "TAXUS ATLAS and TAXUS ATLAS DIRECT STENT Trials: Durable Effectiveness of the TAXUS Liberte Stent and Long-Term Benefit of Direct Stenting". In addition, two-year data from the TAXUS ATLAS Small Vessel and Long Lesion studies will be presented by John A. Ormiston, M.D., in an e-poster session titled "Durable Benefit of TAXUS Liberte vs. TAXUS Express in Small Vessels and Long Lesions in the TAXUS ATLAS SMALL VESSEL and TAXUS ATLAS LONG LESION Trials". TAXUS ATLAS is a global, multi-center, single-arm study designed to demonstrate that the TAXUS Liberte Stent is non-inferior in safety and efficacy to the TAXUS Express Stent. The Company plans to issue a press release at this time.

-- TAXUS ARRIVE diabetic data. A diabetic sub-group analysis from the TAXUS ARRIVE registry will be presented by John M. Lasala, M.D., PhD, in an e-poster session titled "TAXUS Mitigates the Effect of Diabetes on Restenosis Independent of Patient Risk Profile: Two-Year Results from the TAXUS ARRIVE Program". The ARRIVE program is designed to collect and analyze "real-world" safety and clinical outcomes data from the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease. The Company plans to issue a press release at this time.

Tuesday, October 14

-- SYNTAX Study subset data. The latest 12-month outcomes subset data from the SYNTAX trial will be presented by Principal Investigators Patrick W. Serruys, M.D., Ph.D., and Friedrich W. Mohr, M.D., beginning at 11:10 a.m. in the Main Arena of the Washington Convention Center. Dr. Serruys will pres
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death

Post Your Comments:

(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...

(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...

(Date:11/19/2009)...Nov. 19 The D e al m...its Most Admired Corporate Dealmakers for the seco... its Most Admired Dealmaker in pharma/biotech for ...nd divestitures since January 2006. ,, Over the...tfolio with a focus on high-growth, innovation-dri...

Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5 Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6 Heska Announces Launch of New Website 2 Heska Announces Launch of New Website 3 The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2 The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3 Response Times Vary for In Hospital Heart Attacks 53388 1 Response Times Vary for In Hospital Heart Attacks 53388 2 Blood Transfusions Not Linked to Long Term Problems 53386 1 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 1 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 2 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 3 JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 4

[0] Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines [0] Heska Announces Launch of New Website [0] The Deal Names Abbott Top Dealmaker for Second Consecutive Year

... 10:00 a.m. today, Thursday, August 16, 2007, MAL... (Nasdaq: AUXL ) today announced that the Company...g Administration ("FDA") to,resume its phase III c...e,for injection), formerly referred to as AA4500, ...ompany will hold a conference call today,August 16...

...plemental New Drug Application in the Fourth ...ug. 16 Cephalon, Inc. (Nasdaq:,CEPH) today announ...cal,trial of FENTORA(R) (fentanyl buccal tablet) [...d with a broad range of chronic non-cancer pain,co...nce on the primary,endpoint. Results across the 12...

Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5 Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4 Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

(Date:11/21/2009)...nnovative medical apparel company launches men,s l... San Clemente, Calif. (PRWEB) November ...edical apparel, today announced the launch of its ...09, a leading international trade fair for the med...a inaugurates its men,s collection with three vary...

(Date:11/21/2009)...inwood Group ask whether there is a secret to ,alc... London, UK (PRWEB) November 2...e in three of the adult UK population drinking eno...-related liver disease*, it is hardly a surprise t...n programmes and residential centres for help. How...

(Date:11/20/2009)... Nov. 20 The United Sta...e to make essential changes its health reform bill... funding and conscience protection on abortion, pr...lude strong provisions for adequate affordability....ill an "enormous disappointment" that creates new ...

(Date:11/20/2009)... The American Dental As... Administration (FDA) to establish appropriate cla... Citing concern about the safety of whitening prod...it of professional consultation or examination by ...on of chemically based tooth whitening or bleachin...

(Date:11/20/2009)...0 The following is a st...e Nevada Health Care Association: ,, "The Nevad...ks Senate Majority Leader Harry Reid for his leade...r goal of protecting every Nevada seniors, ongoing...ng the strength and viability of our state,s vital...

Breaking Medicine News(10 mins):Health News:Medelita Introduces Men's Lab Coat Collection 2 Health News:Medelita Introduces Men's Lab Coat Collection 3 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3 Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4 Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2 Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2

[0] Medelita Introduces Men's Lab Coat Collection [0] Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not [0] U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability [0] American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products [0] Nevada Health Care Association (NHCA) Supports Majority Leader Reid

..., Nov. 1 Arete Therapeutics Inc. today,announced ... lead compound,AR9281, for the treatment of hypert...e inhibitor of soluble epoxide hydrolase (s-EH), a...armacokinetics and pharmacodynamics for single asc...

... Nov. 1 Amedica Corporation, an,orthopedic implan...nologies, announced today that Ashok Khandkar, Ph....ice President Finance and Chief Financial,Officer,... Hotel in New York City. Mr. Khandkar and Mr. Gal...

...gland and PHILADELPHIA, November 1, Shire plc (LSE...ty biopharmaceutical company announces results for...ghts - Product sales up 41% to $543.1 million; -...ed to be at least 30% (Q2 guidance: at,least 25%)....

...nfirm environmental toxins play role in autism, as..., Nov. 1 The National Autism,Association (NAA) an...school districts to implement the "Greening Your S...nate the serious,dangers posed to children from da...

...wth Over Same Quarter Last Year - - 20%... - FY08 Revenue Projection Raised - ...ed - - Conference Call to be Held at 10:00 a.m....cal 2008 ended September 30, 2007, up 73% from $1....

...Calif., Nov. 1 The Maverick Saloon will,host a tr...ber 8, 2007 from,4 PM until 7 PM to raise research... that claimed the life of the much loved and respe...yvjoneshouse.com . The proceeds from the show wil...

Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent Amedica to Present at CIBC World Markets 18th Annual Healthcare Conference Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter Friends of Warren Zevon To Play at Maverick Saloon - Raising Awareness of Asbestos Cancer, Mesothelioma

...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...

Medicine Products:

Quetiapine Quantitative Plasma & Urinary Amino Acids QuantiFERON-TB Gold (Local Clients Only)Qualitative Tissue Culture

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems a...(/p Schedule of Events Sunday Octobe...),Health